Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:09 PM ET 8-K
Financial Results Soluna Holdings, Inc SLNH

Soluna Holdings Financial Results

Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.

Term
Q3 2026
4:09 PM ET 8-K
Financial Results Entrepreneur Universe Bright Group EUBG

Entrepreneur Universe Bright Group Financial Results

Entrepreneur Universe Bright Group reported Q3 2026 revenue of $0.68 million, a decrease from $1.22 million in the prior year period, resulting in a net loss of $0.22 million. The company noted contracting demand in certain consulting lines but saw initial contributions from its newly established Credit Services segment in Hong Kong.

Term
Q3 2026

“Our third quarter results reflected contracting demand in certain consulting service lines, while digital marketing services and our newly established Credit Services segment contributed revenue during the period. We will continue to manage our operations prudently, strengthen our service capabilities and pursue opportunities to expand our revenue base in line with our long-term business objectives.”

Guolin Tao, CEO of EUBG
4:09 PM ET 8-K
Financial Results Kyntra Bio, Inc. KYNB

Kyntra Bio Financial Results

Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.

Term
Q3 2026

“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”

Thane Wettig, Chief Executive Officer of Kyntra Bio
4:09 PM ET 10-Q
Financial Results 374Water Inc. SCWO

374Water Q3 2026 Results: Net Loss of $3.26M, Loss Narrows

374Water Inc. reported a significant revenue increase to $3.47 million for the nine months ended September 30, 2026, compared to $1.90 million in the prior year period. Despite improved gross margins, the company incurred a net loss of $10.53 million due to high operating expenses and a $1.02 million loss on debt extinguishment.

Key figure
Net loss $3.26M
4:09 PM ET 10-Q
Financial Results Sbig Holdings, Inc. SBIG

Sbig Holdings Q3 2026 Results: Net Income $3.21M, Up 1366.7% YoY

SBIG Holdings, Inc. reported a net income of $3.2 million for the quarter ended September 30, 2026, primarily driven by a $1.7 million gain from discontinued operations and a $1.6 million gain on troubled debt restructuring. The company transferred its operating subsidiary, SpringBig, Inc., in July 2026 and currently has no operating business or revenue as it seeks a strategic transaction.

Key figure
Net income $3.21M · +1366.7% YoY
4:09 PM ET 8-K
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Financial Results

Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.

Term
Q3 2026

“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”

Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
4:09 PM ET 10-Q
Financial Results FS Credit Real Estate Income Trust, Inc.

FS Credit Real Estate Income Trust Q3 2026 Results: Net Income $30.3M, Down 49.4% YoY

For the nine months ended September 30, 2026, FS Credit Real Estate Income Trust reported net income of $98.8 million, a decrease from $129.6 million in the prior year period. Total assets decreased to $11.4 billion from $11.8 billion at year-end 2025, primarily driven by a reduction in mortgage loans held in securitization trusts.

Key figure
Net income $30.3M · -49.4% YoY
4:09 PM ET 10-Q
Financial Results First Breach, Inc. FBDT

First Breach Q3 2026 Results: Net Loss of $25.3M, Loss Widens

First Breach, Inc. reported a significant increase in net loss to $53.8 million for the nine months ended September 30, 2026, driven by a surge in selling, general, and administrative expenses and stock-based compensation. Despite revenue growth to $0.93 million, the company maintains a negative gross margin and is currently operating as an early-stage, pre-net income entity.

Key figure
Net loss $25.3M
4:09 PM ET 10-Q
Financial Results International Land Alliance Inc. ILAL

International Land Alliance Q3 2026 Results: Net Loss of $1.57M, Loss Narrows

International Land Alliance Inc. reported net revenues of $2.20 million for the nine months ended September 30, 2026, but incurred a net loss of $8.27 million due to high general and administrative expenses and interest costs. The company's total assets remained stable at approximately $32.36 million, while stockholders' equity increased to $8.85 million following significant common stock issuances and debt conversions.

Key figure
Net loss $1.57M
4:08 PM ET 10-Q
Financial Results Soluna Holdings, Inc SLNH ▶ Call

Soluna Holdings Q3 2026 Results: Net Loss of $28.7M, Loss Widens

Soluna Holdings, Inc. is a non-accelerated filer and smaller reporting company focused on Bitcoin mining and high-performance computing (HPC) data centers. As of November 12, 2026, the company reported 258,827,640 shares of common stock outstanding and is expanding its services into GPU-as-a-Service and AI-related infrastructure.

Key figure
Net loss $28.7M
4:08 PM ET 10-Q
Financial Results VirnetX Holding Corp VHC

VirnetX Holding Q3 2026 Results: Net Loss of $4.51M, Loss Widens

VirnetX Holding Corp reported zero revenue for the nine months ended September 30, 2026, and a net loss of $13.4 million. The company issued a going concern warning, stating that its current cash and cash equivalents of $10.1 million are insufficient to fund operations for the next twelve months.

Key figure
Net loss $4.51M
4:08 PM ET 10-Q
Financial Results Global Gas Corp HGAS

Global Gas Q3 2026 Results: Net Loss of $19.7K, Loss Narrows

Global Gas Corporation reported a net loss of $87,641 for the nine months ended September 30, 2026, compared to a loss of $21,844 in the prior year period. The company remains a nascent project developer with zero revenue in 2026 and a total stockholders' deficit of $383,971 as of the reporting date.

Key figure
Net loss $19.7K
4:08 PM ET 10-Q
Financial Results 5E Advanced Materials, Inc. FEAM

5E Advanced Materials Q1 2026 Results: Net Loss of $13.1M, Loss Widens

5E Advanced Materials, Inc. has transitioned from a pre-revenue development stage company to a revenue-generating producer following a recent acquisition. However, the company reports substantial doubt regarding its ability to continue as a going concern, citing the need for significant additional funding to maintain operations and advance the Fort Cady Project.

Key figure
Net loss $13.1M
4:08 PM ET 10-Q
Financial Results Entrepreneur Universe Bright Group EUBG

Entrepreneur Universe Bright Group Q3 2026 Results: Net Loss of $222K

Entrepreneur Universe Bright Group reported a net loss of $178,346 for the nine months ended September 30, 2026, compared to a net income of $1,001,450 in the prior year period, driven by a 35% decline in revenue. During the period, the company expanded into the Fintech sector through the acquisition of HengYing International Investment Limited and initiated commercial lending activities.

Key figure
Net loss $222K
4:08 PM ET 10-Q
Financial Results Dare Bioscience, Inc. DARE

Dare Bioscience Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.

Key figure
Net loss $3.16M
4:08 PM ET 10-Q
Financial Results Pathfinder Bancorp, Inc. PBHC

Pathfinder Bancorp Q3 2026 Results: Net Income $2.07M, Up 230.5% YoY

For the nine months ended September 30, 2026, Pathfinder Bancorp reported net income of $7.15 million, a significant increase from $3.63 million in the prior year period, primarily driven by a $5.1 million reduction in the provision for credit losses. Total assets grew to $1.49 billion, while shareholders' equity decreased slightly to $118.8 million due to an increase in accumulated other comprehensive loss from available-for-sale securities.

Key figure
Net income $2.07M · +230.5% YoY
4:08 PM ET 10-Q
Financial Results Cycurion, Inc. CYCU

Cycurion Q3 2026 Results: Net Loss of $2.92M, Loss Narrows

Cycurion, Inc. reported revenue of $12.4 million for the nine months ended September 30, 2026, compared to $11.6 million in the prior year period. The company significantly reduced its operating loss to $7.2 million from $18.4 million year-over-year, primarily due to the absence of one-time business combination expenses incurred in 2025.

Key figure
Net loss $2.92M
4:08 PM ET 10-Q
Financial Results Security Midwest Bancorp, Inc. SBMW

Security Midwest Bancorp Q3 2026 Results: Net Income $445K, Up 58.2% YoY

Security Midwest Bancorp reported net income of $1.25 million for the nine months ended September 30, 2026, an increase from $1.03 million in the prior year period. The company experienced significant loan growth, with net loans increasing to $137.0 million from $117.8 million at year-end 2025, while total assets remained stable at approximately $255.9 million.

Key figure
Net income $445K · +58.2% YoY
4:08 PM ET 10-Q
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Q3 2026 Results: Net Loss of $17.9M, Loss Narrows

For the nine months ended September 30, 2026, Acrivon Therapeutics reported a net loss of $54.9 million, a slight improvement from the $58.9 million loss in the prior year period. The company's cash position decreased to $47.5 million from $41.5 million at year-end 2025, while short-term investments dropped significantly from $77.1 million to $30.2 million.

Key figure
Net loss $17.9M
4:08 PM ET 10-Q
Financial Results Zoned Properties, Inc. ZDPY

Zoned Properties Q3 2026 Results: Net Income $5.31M, Up 3320.0% YoY

Zoned Properties reported a significant increase in net income to $5.33 million for the nine months ended September 30, 2026, primarily driven by a $5.91 million gain from the sale of rental properties classified as discontinued operations. The company's cash position strengthened substantially to $10.46 million, while continuing operations remained pre-revenue with an operating loss of $1.12 million.

Key figure
Net income $5.31M · +3320.0% YoY
4:08 PM ET 10-Q
Financial Results Myseum.AI, Inc. MYSE

Myseum.AI Q3 2026 Results: Net Loss of $1.95M, Loss Widens

Myseum.AI, Inc. reported a significant net loss of $7.87 million for the nine months ended September 30, 2026, compared to a $4.21 million loss in the prior year, driven by increased operating expenses and a $2.58 million unrealized loss on non-traded equity securities. Total assets decreased from $7.20 million to $3.59 million during the period, primarily due to the devaluation of investments and cash burn from operations.

Key figure
Net loss $1.95M
3:48 PM ET 10-Q
Financial Results Sundance Strategies, Inc. SUND

Sundance Strategies Q2 2026 Results: Net Loss of $191K, Loss Widens

Sundance Strategies, Inc. reported a net loss of $404,106 for the six months ended September 30, 2026, compared to a loss of $798,614 in the prior year period. The company generated no revenue during these periods and continues to operate with a significant stockholders' deficit of $7.5 million as it transitions its business model toward professional services for the life settlement market.

Key figure
Net loss $191K
3:45 PM ET 10-Q
Financial Results KiNRG, Inc. BYOP

KiNRG Q3 2026 Results: Turns Profitable, Net Income $10.9M

KiNRG, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.8 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a massive increase in revenue to $867.3 million, primarily following a major acquisition that expanded the company's contract assets and receivables.

Key figure
Net income $10.9M
3:44 PM ET 8-K
Financial Results Retractable Technologies Inc RVP

Retractable Technologies Financial Results

Retractable Technologies reported Q3 2026 total net sales of $14.1 million, a significant increase from $10.1 million in the prior year period, driven by a 64% increase in unit sales of EasyPoint products. Despite the revenue growth, the company recorded an operating loss of $4.1 million for the quarter as it continues to manage domestic production shifts and tariff mitigation efforts.

Term
Q3 2026
3:44 PM ET 8-K
Financial Results Reading International Inc RDI

Reading International Financial Results

Reading International reported its best third-quarter operating income since 2016, driven by record-breaking box office performance from 'Spider Man: Brand New Day' and 'The Odyssey'. Total revenues grew 25% year-over-year to $65.3 million, while net income turned positive at $0.5 million compared to a loss in the prior year period.

Term
Q3 2026

“Following a strong second quarter, we once again delivered strong operational results in the third quarter 2026 with our third quarter Operating Income, EBITDA, Basic Earnings per Share and Net Income delivering better results than pre-pandemic third quarter periods, despite having sold 10 properties since Q3 2019 and having reduced our global cinema screen count by 5%.”

Ellen Cotter, President and Chief Executive Officer
3:42 PM ET 10-Q
Financial Results Quarta-Rad, Inc. QURT

Quarta-Rad Q3 2026 Results: Net Loss of $42.5K, Loss Narrows

Quarta-Rad, Inc. reported a net loss of $181,456 for the nine months ended September 30, 2026, as it continues to wind down its legacy radiation business to focus on its AI software subsidiary, Sellavir, Inc. Total sales decreased from $162,686 to $129,618 year-over-year, and the company reported a stockholders' deficit of $38,921.

Key figure
Net loss $42.5K
3:42 PM ET 10-Q
Financial Results Polomar Health Services, Inc. PMHS

Polomar Health Services Q3 2026 Results: Net Loss of $514K, Loss Narrows

Polomar Health Services, Inc. reported a significant revenue increase to $3.74 million for the nine months ended September 30, 2026, compared to just $16,174 in the prior year period. Despite this growth, the company incurred a net loss of $829,002 and maintains a stockholders' deficit of $2.84 million, though it achieved positive cash flow from operations of $193,996.

Key figure
Net loss $514K
3:42 PM ET 10-Q
Financial Results Goldenwell Biotech, Inc. GWLL

Goldenwell Biotech Q3 2026 Results: Net Loss of $31.5K, Loss Widens

Goldenwell Biotech Inc. reported a net loss of $86,022 for the nine months ended September 30, 2026, with zero revenue generated during the period. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $1,742,138 and limited cash reserves of $788.

Key figure
Net loss $31.5K
3:26 PM ET 10-Q
Financial Results Reading International Inc RDI

Reading International Q3 2026 Results: Turns Profitable, Net Income $467K

Reading International reported a net income of $0.5 million for the quarter ended September 30, 2026, a significant improvement from a $4.3 million loss in the prior year period, driven by a 25% increase in total revenue. However, for the nine months ended September 30, 2026, the company remains in a net loss position of $5.3 million with a total stockholders' deficit of $22.2 million.

Key figure
Net income $467K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.